Amarin Corp PLC (STU:EH3A)
€ 0.442 -0.038 (-7.92%) Market Cap: 197.44 Mil Enterprise Value: -83.88 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 38/100

Amarin Corporation PLC at 38th Annual J.P Morgan Healthcare Conference Transcript

Jan 15, 2020 / 06:30PM GMT
Release Date Price: €17.5 (+1.74%)
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Hey, good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference this morning with Amarin. We're going to host a Q&A session with the management team right after this. It's just across the hall in the Georgian room. But for the presentation, I'm going to turn it over to the company's CEO, John Thero.

John F. Thero
Amarin Corporation plc - President, CEO & Director

Thank you, Jess, for the introduction. Thank you, everybody, for joining me here today. At this -- in the same room, last year around this time, was presenting to, broad acclaim, both the significant revenue growth we had in the prior year, but also the results of our landmark cardiovascular outcome study for our lead drug, Vascepa. This year, I'm presenting following even further growth in our revenues, but also after the first ever FDA approval of a drug for cardiovascular risk indication that's important, and we'll be talking about.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot